In our study, we found that the percentage of CD34+ CD38low/−CD123+ cells (CD123+ LSCs) was significantly lower in patient with AML with CR than in patients with non-CR and this result came in harmony with the study of Hwang et al., [19] who observed a somewhat higher level of CD123 expression on LSCs in the non-CR group and relapsed group. This evidence concerns the gene CD34 and acute myeloid leukemia.